Androscoggin Valley Hospital | |
59 Page Hill Road, Berlin, New Hampshire 03570 | |
(603) 752-2200 | |
Name | Androscoggin Valley Hospital |
---|---|
Type | Critical Access Hospital |
Location | 59 Page Hill Road, Berlin, New Hampshire |
Ownership | Voluntary non-profit - Private |
Emergency Services | Yes |
Medicare ID (CCN) | 301310 |
NPI Number | 1346575560 |
Organization Name | ANDROSCOGGIN VALLEY HOSPITAL OB |
Address | 59 Page Hill Rd, Berlin, NH 03570 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 603-752-2200 |
News Archive
BioServe has announced a more affordable pricing plan for its vast bank of DNA with comprehensive, de-identified, covariate data that includes age, gender, diet, body mass index (BMI), and race. In addition, each sample has data on the complete diagnostic and treatment history of the donor.
Researchers at The Ohio State University are conducting a study to determine which is more effective for helping children on the autism spectrum: training parents or taking medication.
According dental health experts, changes in diet, un-flouridated bottled water and the habit of "constantly bathing" ones teeth in sugary drinks is to blame for the rising number of decaying and rotten teeth found in children
Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.
› Verified 6 days ago
NPI Number | 1861568743 |
Organization Name | ANDROSCOGGIN VALLEY HOSPITAL, INC. |
Address | 59 Page Hill Rd, Berlin, NH 03570 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 603-326-5867 |
News Archive
BioServe has announced a more affordable pricing plan for its vast bank of DNA with comprehensive, de-identified, covariate data that includes age, gender, diet, body mass index (BMI), and race. In addition, each sample has data on the complete diagnostic and treatment history of the donor.
Researchers at The Ohio State University are conducting a study to determine which is more effective for helping children on the autism spectrum: training parents or taking medication.
According dental health experts, changes in diet, un-flouridated bottled water and the habit of "constantly bathing" ones teeth in sugary drinks is to blame for the rising number of decaying and rotten teeth found in children
Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.
› Verified 6 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
BioServe has announced a more affordable pricing plan for its vast bank of DNA with comprehensive, de-identified, covariate data that includes age, gender, diet, body mass index (BMI), and race. In addition, each sample has data on the complete diagnostic and treatment history of the donor.
Researchers at The Ohio State University are conducting a study to determine which is more effective for helping children on the autism spectrum: training parents or taking medication.
According dental health experts, changes in diet, un-flouridated bottled water and the habit of "constantly bathing" ones teeth in sugary drinks is to blame for the rising number of decaying and rotten teeth found in children
Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.
› Verified 6 days ago
Androscoggin Valley Hospital Critical Access Hospital Location: 59 Page Hill Road, Berlin, New Hampshire 03570 Phone: (603) 752-2200 |